Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 23, 2026, 5:31 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 625–648 of 26,229 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Cancer Patient Clear all
Completed Phase 1Phase 2 Interventional

A Phase I Study of Mozobil in the Treatment of Patients With WHIMS

NCT00967785
View directory record Official record
Conditions
Leukopenia, Neutropenia, Infections, Warts, Myelokathexis
Interventions
Mozobil (TM)
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 75 Years
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2026
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 28, 2026 · Synced Oct 23, 2026, 5:31 AM EDT
Completed Phase 2 Interventional Results available

Study of the Effects of Brilacidin Oral Rinse on Radiation-induced Oral Mucositis in Patients With Head and Neck Cancer

NCT02324335
View directory record Official record
Conditions
Head and Neck Neoplasms, Mucositis
Interventions
Brilacidin, Placebo
Drug · Other
Lead sponsor
Innovation Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
61 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
16
States / cities
Gilbert, Arizona • Lakeland, Florida • Columbus, Georgia + 13 more
Source: ClinicalTrials.gov public record
Updated Jan 16, 2019 · Synced Oct 23, 2026, 5:31 AM EDT
Terminated Phase 1Phase 2 Interventional Results available

A Study of DSP-0509 in Patients With Advanced Solid Tumors to Determine the Safety and the Pharmacokinetic Profile

NCT03416335
View directory record Official record
Conditions
Neoplasms
Interventions
DSP-0509, DSP-0509, Pembrolizumab
Drug
Lead sponsor
Sumitomo Pharma America, Inc.
Industry
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
5
States / cities
Indianapolis, Indiana • Chapel Hill, North Carolina • Philadelphia, Pennsylvania + 2 more
Source: ClinicalTrials.gov public record
Updated May 30, 2024 · Synced Oct 23, 2026, 5:31 AM EDT
Completed Phase 3 Interventional

Dalteparin Low Molecular Weight Heparin for Primary Prophylaxis of Venous Thromboembolism in Brain Tumour Patients

NCT00135876
View directory record Official record
Conditions
Venous Thromboembolism, Brain Tumors
Interventions
dalteparin
Drug
Lead sponsor
Ontario Clinical Oncology Group (OCOG)
Other
Eligibility
18 Years and older
Enrollment
512 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2006
U.S. locations
3
States / cities
Evanston, Illinois • Detroit, Michigan • Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Apr 27, 2007 · Synced Oct 23, 2026, 5:31 AM EDT
Terminated Phase 2 Interventional Results available

Liver Directed RT + Chemo-immunotherapy for ES-SCLC

NCT04923776
View directory record Official record
Conditions
Small-cell Lung Cancer
Interventions
Carboplatin, Etoposide, Atezolizumab, Stereotactic Body Radiation Therapy (SBRT)
Drug · Radiation
Lead sponsor
Brian Henick, MD
Other
Eligibility
18 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Dec 30, 2024 · Synced Oct 23, 2026, 5:31 AM EDT
Completed Phase 2 Interventional Results available

Paclitaxel and Carboplatin in Treating Patients With Persistent or Recurrent Stage III or Stage IV Uterine Cancer

NCT00112489
View directory record Official record
Conditions
Sarcoma
Interventions
carboplatin, paclitaxel
Drug
Lead sponsor
Gynecologic Oncology Group
Network
Eligibility
18 Years to 120 Years · Female only
Enrollment
55 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2005
U.S. locations
99
States / cities
Birmingham, Alabama • Los Angeles, California • New Britain, Connecticut + 73 more
Source: ClinicalTrials.gov public record
Updated Sep 25, 2018 · Synced Oct 23, 2026, 5:31 AM EDT
Completed Phase 1Phase 2 Interventional Results available

A Study of Belinostat + Carboplatin or Paclitaxel or Both in Patients With Ovarian Cancer in Need of Relapse Treatment

NCT00421889
View directory record Official record
Conditions
Ovarian Cancer, Epithelial Ovarian Cancer, Fallopian Tube Cancer, Bladder Cancer
Interventions
belinostat, Paclitaxel, Carboplatin
Drug
Lead sponsor
Valerio Therapeutics
Industry
Eligibility
18 Years and older · Female only
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2009
U.S. locations
7
States / cities
Newport Beach, California • Orlando, Florida • Covington, Louisiana + 4 more
Source: ClinicalTrials.gov public record
Updated Jul 28, 2015 · Synced Oct 23, 2026, 5:31 AM EDT
Completed Phase 2 Interventional Results available

Sirolimus and Azacitidine in Treating Patients With High Risk Myelodysplastic Syndrome or Acute Myeloid Leukemia That is Recurrent or Not Eligible for Intensive Chemotherapy

NCT01869114
View directory record Official record
Conditions
Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities, Adult Acute Myeloid Leukemia With Del(5q), Adult Acute Myeloid Leukemia With Inv(16)(p13;q22), Adult Acute Myeloid Leukemia With t(15;17)(q22;q12), Adult Acute Myeloid Leukemia With t(16;16)(p13;q22), Adult Acute Myeloid Leukemia With t(8;21)(q22;q22), de Novo Myelodysplastic Syndromes, Myelodysplastic Syndrome With Isolated Del(5q), Previously Treated Myelodysplastic Syndromes, Recurrent Adult Acute Myeloid Leukemia
Interventions
Sirolimus, Azacitidine
Drug
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University
Other
Eligibility
18 Years and older
Enrollment
57 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2024
U.S. locations
5
States / cities
Sewell, New Jersey • Abington, Pennsylvania • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Dec 10, 2025 · Synced Oct 23, 2026, 5:31 AM EDT
Completed No phase listed Observational

Myelofibrosis and Essential Thrombocythemia Observational Study (MOST)

NCT02953704
View directory record Official record
Conditions
MPN (Myeloproliferative Neoplasms)
Interventions
Not listed
Lead sponsor
Incyte Corporation
Industry
Eligibility
18 Years and older
Enrollment
1,469 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2022
U.S. locations
114
States / cities
Huntsville, Alabama • Tempe, Arizona • Tucson, Arizona + 111 more
Source: ClinicalTrials.gov public record
Updated May 13, 2022 · Synced Oct 23, 2026, 5:31 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Study of IDO Inhibitor and Temozolomide for Adult Patients With Primary Malignant Brain Tumors

NCT02052648
View directory record Official record
Conditions
Glioblastoma Multiforme, Glioma, Gliosarcoma, Malignant Brain Tumor
Interventions
Indoximod, Temozolomide, Bevacizumab, Stereotactic Radiation
Drug · Radiation
Lead sponsor
NewLink Genetics Corporation
Industry
Eligibility
16 Years and older
Enrollment
160 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2019
U.S. locations
17
States / cities
Castro Valley, California • Los Angeles, California • Orange, California + 14 more
Source: ClinicalTrials.gov public record
Updated Mar 27, 2024 · Synced Oct 23, 2026, 5:31 AM EDT
Completed Phase 2 Interventional

Immunization of HLA-A201 Patients With Metastatic Melanoma Using a Combination of Immunodominant Peptides From Three Melanoma Antigens, MART-1, GP100 and Tyrosinase

NCT00001685
View directory record Official record
Conditions
Melanoma, Neoplasm Metastasis
Interventions
Immunodominant peptides from three melanoma antigens, MART-1, GP100 and tyrosinase
Biological
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
Not listed
Enrollment
114 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1997 – 2000
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 4, 2008 · Synced Oct 23, 2026, 5:31 AM EDT
Completed Phase 3 Interventional Results available

Selenium in Preventing Tumor Growth in Patients With Previously Resected Stage I Non-small Cell Lung Cancer

NCT00008385
View directory record Official record
Conditions
Lung Cancer
Interventions
placebo, selenium
Other · Drug
Lead sponsor
ECOG-ACRIN Cancer Research Group
Network
Eligibility
18 Years and older
Enrollment
1,772 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2019
U.S. locations
515
States / cities
Mobile, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 339 more
Source: ClinicalTrials.gov public record
Updated Jul 5, 2023 · Synced Oct 23, 2026, 5:31 AM EDT
Completed Phase 2 Interventional

Combination Chemotherapy Followed by Bone Marrow Transplantation in Treating Patients With Rare Cancer

NCT00002515
View directory record Official record
Conditions
Childhood Germ Cell Tumor, Extragonadal Germ Cell Tumor, Head and Neck Cancer, Kidney Cancer, Liver Cancer, Lymphoma, Neuroblastoma, Ovarian Cancer, Retinoblastoma, Sarcoma, Testicular Germ Cell Tumor
Interventions
filgrastim, carboplatin, thiotepa, topotecan hydrochloride, autologous bone marrow transplantation, bone marrow ablation with stem cell support, in vitro-treated bone marrow transplantation
Biological · Drug · Procedure
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
Up to 21 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
1992 – 2005
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 24, 2013 · Synced Oct 23, 2026, 5:31 AM EDT
Active, not recruiting Phase 1 Interventional

CBM588 in Improving Clinical Outcomes in Patients Who Have Undergone Donor Hematopoietic Stem Cell Transplant

NCT03922035
View directory record Official record
Conditions
Hematopoietic and Lymphoid Cell Neoplasm
Interventions
Best Practice, Clostridium butyricum CBM 588 Probiotic Strain
Other · Drug
Lead sponsor
City of Hope Medical Center
Other
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2027
U.S. locations
1
States / cities
Duarte, California
Source: ClinicalTrials.gov public record
Updated Oct 15, 2026 · Synced Oct 23, 2026, 5:31 AM EDT
Terminated Phase 1Phase 2 Interventional Results available

Randomized Efficacy Study of TPI 287 to Treat Primary Refractory or Early Relapsed Neuroblastoma

NCT01505608
View directory record Official record
Conditions
Neuroblastoma
Interventions
TPI 287, Temozolomide, Irinotecan
Drug
Lead sponsor
Giselle Sholler
Other
Eligibility
12 Months to 21 Years
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
8
States / cities
Phoenix, Arizona • San Diego, California • Hartford, Connecticut + 5 more
Source: ClinicalTrials.gov public record
Updated Aug 6, 2024 · Synced Oct 23, 2026, 5:31 AM EDT
Completed Phase 2 Interventional Results available

Phase 2 Study of VELCADE (Bortezomib) in Patients With Relapsed Follicular Lymphoma

NCT00715208
View directory record Official record
Conditions
Relapsed Follicular Lymphoma
Interventions
rituximab, cyclophosphamide, doxorubicin, VELCADE, prednisone
Drug
Lead sponsor
Millennium Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
55 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
42
States / cities
Muscle Shoals, Alabama • Burbank, California • Fountain Valley, California + 38 more
Source: ClinicalTrials.gov public record
Updated Apr 29, 2013 · Synced Oct 23, 2026, 5:31 AM EDT
Completed Phase 1 Interventional

Lenvatinib and Weekly Paclitaxel for Patients With Recurrent Endometrial or Ovarian Cancer

NCT02788708
View directory record Official record
Conditions
Fallopian Tube Carcinoma, Recurrent Ovarian Cancer, Primary Peritoneal Carcinoma, Recurrent Endometrial Cancer
Interventions
Lenvatinib Mesylate, Paclitaxel, Pharmacological Study
Drug · Other
Lead sponsor
Floor Backes
Other
Eligibility
18 Years and older · Female only
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2022
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Sep 19, 2022 · Synced Oct 23, 2026, 5:31 AM EDT
Completed Early Phase 1 Interventional

Peripheral Blood Stem Cell (PBSC) Mobilization in Patients With Relapsed Lymphoma Treated With Bendamustine

NCT01022021
View directory record Official record
Conditions
Lymphoma
Interventions
Rituximab, Bendamustine
Drug
Lead sponsor
University of Kansas Medical Center
Other
Eligibility
18 Years to 70 Years
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2015
U.S. locations
1
States / cities
Kansas City, Kansas
Source: ClinicalTrials.gov public record
Updated Jan 10, 2017 · Synced Oct 23, 2026, 5:31 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Scaling CRC Screening Through Outreach, Referral, and Engagement (SCORE)

NCT04406714
View directory record Official record
Conditions
Colorectal Cancer
Interventions
Trial Mailed FIT Intervention - Age Group 50-75, Sub-Study Mailed FIT Intervention Enhanced Envelope - Age Group 45-49, Sub-Study Mailed FIT Active Comparator Plain Envelope - Age Group 45-49
Behavioral
Lead sponsor
UNC Lineberger Comprehensive Cancer Center
Other
Eligibility
45 Years to 75 Years
Enrollment
4,318 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2024
U.S. locations
2
States / cities
Ahoskie, North Carolina • Hendersonville, North Carolina
Source: ClinicalTrials.gov public record
Updated May 15, 2026 · Synced Oct 23, 2026, 5:31 AM EDT
Completed Phase 3 Interventional Results available

Carboplatin and Paclitaxel With or Without Bevacizumab in Treating Patients With Stage III or Stage IV Ovarian Epithelial, Primary Peritoneal, or Fallopian Tube Cancer

NCT00262847
View directory record Official record
Conditions
Fallopian Tube Clear Cell Adenocarcinoma, Fallopian Tube Endometrioid Adenocarcinoma, Fallopian Tube Mucinous Adenocarcinoma, Fallopian Tube Serous Adenocarcinoma, Fallopian Tube Transitional Cell Carcinoma, Malignant Ovarian Mixed Epithelial Tumor, Ovarian Brenner Tumor, Ovarian Clear Cell Adenocarcinoma, Ovarian Endometrioid Adenocarcinoma, Ovarian Mucinous Adenocarcinoma, Ovarian Serous Adenocarcinoma, Ovarian Transitional Cell Carcinoma, Primary Peritoneal Serous Adenocarcinoma, Stage IIIA Fallopian Tube Cancer, Stage IIIA Ovarian Cancer, Stage IIIA Primary Peritoneal Cancer, Stage IIIB Fallopian Tube Cancer, Stage IIIB Ovarian Cancer, Stage IIIB Primary Peritoneal Cancer, Stage IIIC Fallopian Tube Cancer, Stage IIIC Ovarian Cancer, Stage IIIC Primary Peritoneal Cancer, Stage IV Fallopian Tube Cancer, Stage IV Ovarian Cancer, Stage IV Primary Peritoneal Cancer, Undifferentiated Fallopian Tube Carcinoma, Undifferentiated Ovarian Carcinoma
Interventions
Bevacizumab, Carboplatin, Laboratory Biomarker Analysis, Paclitaxel, Placebo, Quality-of-Life Assessment
Biological · Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older · Female only
Enrollment
1,873 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2015
U.S. locations
614
States / cities
Anniston, Alabama • Birmingham, Alabama • Huntsville, Alabama + 395 more
Source: ClinicalTrials.gov public record
Updated Jul 23, 2019 · Synced Oct 23, 2026, 5:31 AM EDT
Withdrawn Not applicable Interventional

Time Restricted Eating (TRE) in Metastatic Head and Neck Squamous Cell Cancer (mHNSCC) or Unresectable or Metastatic Renal Cell Carcinoma (RCC)

NCT06603155
View directory record Official record
Conditions
Metastatic Head-and-neck Squamous-cell Carcinoma, Unresectable Renal Cell Carcinoma, Metastatic Renal Cell Carcinoma
Interventions
Time restricted eating (TRE)
Behavioral
Lead sponsor
Duke University
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Dec 19, 2025 · Synced Oct 23, 2026, 5:31 AM EDT
Completed Phase 1 Interventional

SU5416 and Carboplatin to Treat Ovarian Cancer

NCT00006155
View directory record Official record
Conditions
Fallopian Tube Neoplasm, Ovarian Cancer, Peritoneal Neoplasm
Interventions
SU5416 and carboplatin
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
Female only
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2001
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 4, 2008 · Synced Oct 23, 2026, 5:31 AM EDT
Completed Phase 1Phase 2 Interventional

Phase I/II Study of DFP-10917 in Patients With Acute Leukemia

NCT01702155
View directory record Official record
Conditions
Acute Myeloid Leukemia, Acute Lymphocytic Leukemia
Interventions
DFP-10917
Drug
Lead sponsor
Delta-Fly Pharma, Inc.
Industry
Eligibility
18 Years and older
Enrollment
69 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2017
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Oct 25, 2019 · Synced Oct 23, 2026, 5:31 AM EDT
Completed Not applicable Interventional Results available

Safety of Stool Transplant for Patients With Difficult to Treat C. Difficile Infection

NCT02770326
View directory record Official record
Conditions
C. Difficile Infection, Cancer
Interventions
Fecal Microbiota Transplantation (FMT)
Biological
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2024
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 8, 2025 · Synced Oct 23, 2026, 5:31 AM EDT